• 1. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 2. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 3. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 4. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

Exploring Adenosine, 8-bromo-,cyclic 3',5'-[hydrogen [P(R)]-phosphorothioate] (9CI) (CAS No. 129735-00-8): A Key Player in Biomedical Research

In the realm of nucleotide analogs, Adenosine, 8-bromo-,cyclic 3',5'-[hydrogen [P(R)]-phosphorothioate] (9CI) (CAS No. 129735-00-8) stands out as a chemically modified derivative of adenosine. This compound, often abbreviated as 8-Br-cAMPS, is a cyclic adenosine monophosphate (cAMP) analog with a bromine substitution at the 8-position and a phosphorothioate modification. These structural alterations enhance its stability and biological activity, making it a valuable tool in signal transduction studies and drug discovery.

The 8-bromo substitution in this compound increases its resistance to enzymatic degradation, while the phosphorothioate backbone improves membrane permeability. These features are particularly relevant in contemporary research on G-protein-coupled receptors (GPCRs) and protein kinase A (PKA) pathways, which are hot topics in cancer therapy and metabolic disorders. Researchers frequently search for "cAMP analogs in cancer research" or "GPCR signaling modulators," highlighting the growing interest in this field.

One of the most compelling applications of Adenosine, 8-bromo-,cyclic 3',5'-[hydrogen [P(R)]-phosphorothioate] (9CI) lies in its ability to mimic the effects of endogenous cAMP. This property is exploited in studies focusing on cell proliferation, apoptosis, and immune response modulation. For instance, recent publications have explored its role in neurodegenerative diseases, such as Alzheimer's and Parkinson's, where cAMP signaling is dysregulated. Keywords like "cAMP and neurodegeneration" or "phosphorothioate analogs in neurology" are increasingly popular in academic searches.

From a technical perspective, the synthesis and purification of 129735-00-8 require specialized expertise due to its complex stereochemistry. The P(R)-phosphorothioate configuration is critical for its biological activity, as it determines the compound's interaction with downstream effectors. This nuance is often overlooked in generic discussions but is a focal point for researchers querying "stereospecific cAMP analogs" or "phosphorothioate synthesis techniques."

In the context of personalized medicine, Adenosine, 8-bromo-,cyclic 3',5'-[hydrogen [P(R)]-phosphorothioate] (9CI) offers potential as a therapeutic agent or research probe. Its ability to selectively activate cAMP-dependent pathways aligns with the trend toward targeted therapies, a subject dominating forums like "precision medicine breakthroughs." Moreover, its utility in high-throughput screening (HTS) assays makes it indispensable for identifying novel kinase inhibitors or receptor agonists.

Despite its niche applications, the compound's commercial availability and well-documented protocols have fueled its adoption in both academia and industry. Searches for "buy 8-Br-cAMPS" or "cAMP analog suppliers" reflect this demand. However, users must ensure compliance with local regulations, as nucleotide analogs often fall under strict research-use-only classifications.

Looking ahead, the integration of Adenosine, 8-bromo-,cyclic 3',5'-[hydrogen [P(R)]-phosphorothioate] (9CI) into AI-driven drug discovery platforms could revolutionize its applications. With machine learning models predicting cAMP-mediated interactions, this compound may unlock new avenues in autoimmune disease research or regenerative medicine. Such innovations resonate with trending queries like "AI in pharmacology" or "cAMP and tissue engineering."

In summary, 129735-00-8 exemplifies the intersection of chemistry and biology, offering insights into fundamental cellular processes while addressing modern biomedical challenges. Its versatility ensures its relevance in evolving fields, from immunotherapy to neuroscience, making it a staple in the toolkit of forward-thinking researchers.

• 118275-99-3(Adenosine, cyclic2',3'-(hydrogen phosphorothioate), (R)- (9CI))
• 19341-57-2(Adenosine,5'-(dihydrogen phosphorothioate))
• 143832-09-1(Ppp-AA)
• 107133-74-4(Adenosine, 5'-(O-methylhydrogen phosphorothioate), (R)- (9CI))
• 23645-17-2(Adenosine, cyclic3',5'-(hydrogen phosphorothioate))
• 123334-12-3(8-Bromoadenosine 3',5'-Cyclic Monophosphate Sodium Salt Monohydrate)
• 118276-00-9(Adenosine, cyclic2',3'-(hydrogen phosphorothioate), (S)- (9CI))
• 23583-48-4(8-Bromoadenosine 3',5'-Cyclic Monophosphate)
• 23583-49-5(2'-Adenylic acid,8-bromo- (9CI))
• 23567-96-6(8-Bromo-AMP)